Drugs / ateganosine

Trials 3

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT07446257 Sep 2026 → Sep 2029 expected hepatocellular carcinoma University of Texas Southwestern Medical Center Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT05208944 Jun 2022 → Sep 2027 expected non-small cell lung carcinoma Maia Biotechnology Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT06908304 Dec 2025 → Jul 2027 expected non-small cell lung carcinoma Maia Biotechnology Recruiting No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ateganosine ClinicalTrials.gov intervention name — accepted as the source's own label NCT07446257 ↗
Known as 2'-deoxy-6-thioguanosine ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as 2'-deoxythioguanosine ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as 2'-desoxy-6-thioguanosine ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as 6-Thio-2'-Deoxyguanosine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06908304 ↗
1

NCT05208944 ↗

Known as Ateganosina ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as Beta-2'-deoxythioguanosine ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as NSC-71261 ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as Thio ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Known as Thioguanine deoxyriboside ChEMBL registry synonym — accepted as the source's own label CHEMBL3250476 ↗
Modality Small molecule “small molecule telomere targeting agent” NCT05208944 ↗
Route Intravenous “as intravenous (IV) infusion” NCT05208944 ↗